Nitrogen Containing (e.g., Anilides, Etc.) Patents (Class 514/166)
-
Patent number: 6143734Abstract: A compound comprising a non-steroidal antiinflammatory agent to which is directly or indirectly linked an NO group, a compound comprising an enolic anilide non-steroidal antiinflammatory agent to which is directly or indirectly linked an NO.sub.2 group, a pharmaceutical composition including the compounds and methods of treatment of pain and/or inflammation using the compounds and compositions are disclosed. Also disclosed is a composition comprising a non-steroidal antiinflammatory agent and a compound that donates, transfers or releases nitric oxide.Type: GrantFiled: January 31, 2000Date of Patent: November 7, 2000Assignee: NitroMed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
-
Patent number: 6117859Abstract: A method of treating chronic inflammation in a mammal is disclosed which comprises contacting the affected area with an amount sufficient to ameliorate the inflammatory condition, of a compound of the following formula: ##STR1## wherein Z is a substituted phenyl ring, R is an alkylsulfonyl group of 1-20 carbon atoms, and X is selected from the group consisting of --CN, --NO.sub.2, --H, halogen, lower alkyl and lower haloalkyl.Type: GrantFiled: September 28, 1999Date of Patent: September 12, 2000Assignee: The Research Foundation of State University of New YorkInventors: Richard T. Evans, Robert A. Coburn, Robert J. Genco, Joseph A. Dunn
-
Patent number: 6045827Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.Type: GrantFiled: August 19, 1997Date of Patent: April 4, 2000Assignee: Meri Charmyne RussellInventor: Meri Charmyne Russell
-
Patent number: 6043232Abstract: A compound comprising a non-steroidal antiinflammatory agent to which is directly or indirectly linked an NO group, a compound comprising an enolic anilide non-steroidal antiinflammatory agent to which is directly or indirectly linked an NO.sub.2 group, a pharmaceutical composition including the compounds and methods of treatment of pain and/or inflammation using the compounds and compositions are disclosed. Also disclosed is a composition comprising a non-steroidal antiinflammatory agent and a compound that donates, transfers or releases nitric oxide.Type: GrantFiled: January 22, 1999Date of Patent: March 28, 2000Assignee: NitroMed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
-
Patent number: 6043233Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.Type: GrantFiled: January 22, 1999Date of Patent: March 28, 2000Assignee: NitroMed, Inc.Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
-
Patent number: 5958911Abstract: A method of treating inflammation in a mammal, which comprises contacting the affected area with an amount sufficient to ameliorate the inflammatory condition, of a compound of the following formula ##STR1## in a pharmaceutically acceptable carrier containing a detergent, where Z is a substituted phenyl, R is a substituted or unsubstituted alkylsulfonyl group from 1 to 20 carbon atoms and X is --CN, --NO.sub.2, --H, halogen, lower alkyl or lower haloalkyl radical.Type: GrantFiled: November 4, 1997Date of Patent: September 28, 1999Assignees: The Research Foundation of State University of New York, Therex Technologies, Inc.Inventors: Richard T. Evans, Robert A. Coburn, Robert A. Genco, Joseph A. Dunn
-
Patent number: 5905073Abstract: The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite or an oxidation product of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite or an oxidation product of an active matabolite thereof.Type: GrantFiled: July 11, 1996Date of Patent: May 18, 1999Assignee: Salix Pharmaceuticals, Inc.Inventors: Lorin K. Johnson, Marvin H. Sleisenger
-
Patent number: 5869471Abstract: The present invention provides methods of treating a human or other animal subject afflicted with arthritis, including rheumatoid, arthritis and osteoarthritis, comprising a sixty (60)-day treatment period, comprised of an optional NSAID administration regimen and a phosphonate administration regimen, wherein(a) said optional NSAID administration regimen which comprises the administration to said subject of NSAIDs at a level of from 20% to 80%, preferably 20% to 70%, most preferably 20% to 50% of the conventionally prescribed daily dose on each day that said NSAID is administered; provided that said NSAID is administered in sufficient quantities and on a sufficient number of days to alleviate symptoms of inflammation, and wherein(b) said phosphonate administration regimen comprises the administration to said subject of a phosphonate at a dose equivalent to a systemic level of from about 0.0005 mgP/kg to about 1.Type: GrantFiled: June 7, 1995Date of Patent: February 9, 1999Assignee: The Proctor & Gamble CompanyInventors: Kristine Hovancik, Marion David Francis, Richard Allen Underwood
-
Patent number: 5869067Abstract: The present invention relates to new aromatic compounds, to their preparation and to their use in human and veterinary medicine and in cosmetic compositions.Type: GrantFiled: September 26, 1994Date of Patent: February 9, 1999Assignee: Centre International De Recherches Dermatologiques Galderma (CIRD Galderma)Inventors: Jean-Phillippe Rocher, Jean-Michel Bernardon
-
Patent number: 5753239Abstract: Bi-aromatic compounds are provided along with methods for their preparation and use.Type: GrantFiled: June 6, 1995Date of Patent: May 19, 1998Assignee: Centre International de Recherches Dematologiques Galderma (Cird Galderma)Inventors: Jean-Philippe Rocher, Jean-Michel Bernardon
-
Patent number: 5750559Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.Type: GrantFiled: August 5, 1994Date of Patent: May 12, 1998Assignee: Sebastiano BiancoInventor: Sebastiano Bianco
-
Patent number: 5731302Abstract: The invention discloses new compositions of mesalazine in the form of aqueous suspensions, characterized in that they are more stable than those of the prior art. The compositions contain colloidal cellulose and one or more hydrophilic thickening agents.Type: GrantFiled: September 30, 1996Date of Patent: March 24, 1998Assignee: Crinos Industria Farmacobiologica S.p.A.Inventors: Giancarlo Farolfi, Franco Lattuada, Laura Ferro
-
Patent number: 5725872Abstract: A composition for a foam and a process for preparing it are provided, the composition including by weight (a) more than 25% of an active ingredient in powder form; (b) from 1 to 20% of a surfactant; the balance being composed of water, wherein the powder of the active ingredient has a particle size below 20 .mu.m. Foams, notably for rectal administration, containing this composition with a propellant gas are also provided.Type: GrantFiled: September 17, 1996Date of Patent: March 10, 1998Assignee: Ferring BVInventors: Andre Stamm, Sibel Fuchs nee Sibel Cepik, Pascal Wehrle
-
Patent number: 5716648Abstract: Compositions for use in the regulation of subnormal pH values in intestinal tract and for treatment of bowel diseases. The compositions comprise a coating and a substantially insoluble alkaline material confined within said coating, the composition being adapted so as to ensure the availability of an amount of said pH regulating alkaline material in the lumen of the gastrointestinal tract exhibiting subnormal pH values. E.g. In the proximal small intestine, the mid small intestine, the distal small intestine, the caecum, the ascending colon, the transverse colon, the descending colon, the sigmoid colon and/or the rectum. The compositions may also comprise a medicament for treatment of bowel disease, e.g. 5-aminosalicylic acid for the treatment of Crohn's disease and colitis ulcerosa. The administration may be oral composition or enemas or suppositories.Type: GrantFiled: December 21, 1995Date of Patent: February 10, 1998Assignee: Farmaceutisk Laboratorium Ferring A/SInventors: S.o slashed.ren Halskov, Svenn Kluver Jepsen
-
Patent number: 5668123Abstract: Method of treating venous insufficiency and venous ulcers by administering to a patient in need thereof an effective amount of sulphasalazine or 5-aminosalicylic acid.Type: GrantFiled: August 30, 1996Date of Patent: September 16, 1997Assignee: SynthelaboInventor: Christopher Berry
-
Patent number: 5583113Abstract: A method for inducing thrombolysis, which method comprises administering to a patient a thrombolytically effective amount of a thrombin inhibitor which acts at the active site of thrombin, in the absence of exogenous plasminogen activator. The inhibitor is preferably argatroban, D-Phe-Pro-Arg-chloromethyl ketone, or Ac-(D-Phe)-Pro-boro-Arg-OH.Type: GrantFiled: February 13, 1995Date of Patent: December 10, 1996Assignee: SynthelaboInventors: Christopher Berry, Patrice Ferrari
-
Patent number: 5541170Abstract: A solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent is coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH7 but soluble in colonic intestinal juice, in a sufficient amount that the oral dosage form remains intact until it reaches the colon. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. The invention has particular application to dosage forms of prednisolone and salts thereof, indomethacin, ibuprofen, and, especially, 5-amino-salicylic acid.Type: GrantFiled: March 10, 1995Date of Patent: July 30, 1996Assignee: Tillotts Pharma AGInventors: John Rhodes, Brian K. Evans
-
Patent number: 5541171Abstract: A solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent is coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH7 but soluble in colonic intestinal juice, in a sufficient amount that the oral dosage form remains intact until it reaches the colon. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. The invention has particular application to dosage forms of prednisolone and salts thereof, indomethacin, ibuprofen, and, especially, 5-amino-salicylic acid.Type: GrantFiled: May 23, 1995Date of Patent: July 30, 1996Assignee: Tillotts Pharma AGInventors: John Rhodes, Brian K. Evans
-
Patent number: 5527523Abstract: Hydroquinone amino-acid esters having formula (I), pharmaceutical or cosmetic compositions containing them, particularly dermatological compositions having pigment-removing activity, and the pharmaceutical, cosmetic or aesthetic uses thereof. The preparation of these novel hydroquinone esters from natural amino-acid derivatives is also described.Type: GrantFiled: October 13, 1992Date of Patent: June 18, 1996Assignee: Virbac S.A.Inventors: Claude Laruelle, Bernard Raynier, Guy Derrieu
-
Patent number: 5519014Abstract: A medicine for treating non-inflammatory and non-infectious bowel disorders, such as irritable bowel syndrome, constipation, non-ulcer dyspepsia, gastro-oesophageal reflux with or without oesophagitis, and diverticular disease, comprising a salicylic acid derivative, such as any one of sulfasalazine, 5-aminosalicylic acid, 4-aminosalicylic acid, and benzalazine, or a combination of any two or more thereof. The treatment of those disorders comprises taking the medicine by mouth to provide a dosage rate of the salicylic acid derivative of from 200 mg to 18 g per day.Type: GrantFiled: June 17, 1994Date of Patent: May 21, 1996Inventor: Thomas J. Borody
-
Patent number: 5498608Abstract: The present invention provides a method of colon cancer chemoprevention or chemotherapy comprising administering to an individual suffering from colon cancer or at risk to develop colon cancer a pharmaceutical composition comprising an effective amount of a 2-hydroxy-5-phenylazobenzoic acid derivative or an ester of an active metabolite thereof, or a pharmacologically acceptable salt of the 2-hydroxy-5-phenylazobenzoic acid derivative or an ester or an active metabolite thereof.Type: GrantFiled: January 7, 1994Date of Patent: March 12, 1996Assignee: Salix PharmaceuticalsInventors: Lorin K. Johnson, Marvin H. Sleisenger
-
Patent number: 5405842Abstract: A method for the treatment of asthma, particularly corticosteroid dependent asthma with "steroid sparing" effect, but without serious toxicities prevalent with common "steroid sparing" treatments and medications, comprising the oral administration, in efficacious doses, of sulfasalazine (SSZ) (5-([p-(2-pyridylsulfamoyl) phenyl]azo) salicylic acid) ##STR1## compounds having either the: ##STR2## moiety, or the: ##STR3## moiety. The SSZ and related compounds can be used as an adjuvant for corticosteroid treatments, which permits drastic reduction of the dosage levels of the corticosteroids with concomitant reduction of steroid side effects.Type: GrantFiled: January 28, 1994Date of Patent: April 11, 1995Inventor: Bernard A. Silverman
-
Patent number: 5366967Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.Type: GrantFiled: May 21, 1993Date of Patent: November 22, 1994Assignee: Hoechst AktiengesellschaftInventor: Sebastiano Bianco
-
Patent number: 5352681Abstract: The light, oxidation and storage stability of aqueous 5-ASA suspensions is increased by incorporating in such suspensions an effective amount of titanium dioxide. The resulting stabilized aqueous suspensions are suitable for enema preparations.Type: GrantFiled: December 7, 1993Date of Patent: October 4, 1994Assignee: BYK Nederland BVInventors: Adrianus Wittebrood, Adrianus P. De Jong, Jan Bron
-
Patent number: 5211947Abstract: A method for lowering the blood cholesterol levels in mammals and humans by administering GM-CSF is disclosed.Type: GrantFiled: December 16, 1988Date of Patent: May 18, 1993Assignee: Schering CorporationInventors: Melvin D. Brannan, Hugh E. Black
-
Patent number: 5151415Abstract: A method for treating an epithelial tumor of a viral infection involves repeated applications of a paste of acetylsalicylic acid and water to the infection until it is arrested.Type: GrantFiled: May 23, 1991Date of Patent: September 29, 1992Inventor: Dallas Sirany
-
Patent number: 5140020Abstract: Disclosed herein are a derivative of dihydroxybenzamide represented by the formula(I): ##STR1## wherein (1) R.sup.1 represents a hydrogen atom or a lower alkyl group and R.sup.2 represents a straight chain-alkyl group of 4 to 12 carbon atoms, a branched chain-alkyl group of 4 to 12 carbon atoms, a cyclo-alkyl group of 4 to 12 carbon atoms, ##STR2## wherein n is an integer of 1 to 6, or a pyridyl group which is substituted or unsubstituted, or (2) R.sup.1 and R.sup.2 are cyclized to make a heterocycle containing amino group represented by the formula ##STR3## wherein X represents a nitrogen atom or a methine and Y represents a hydrogen atom, an alkyl group of 1 to 6 carbon atoms or a phenyl group, and a pharmaceutical composition containing the same.Type: GrantFiled: June 20, 1991Date of Patent: August 18, 1992Assignee: Kureha Kagatu Kogyo Kabushiki KaishaInventors: Hitoshi Takita, Sakuo Noda, Yutaka Mukaida, Kazuyoshi Inada, Mari Toji, Fumihiko Kimura, Toyohiko Nitta, Kohju Watanabe, Kiyonori Umekawa, Hidetoshi Kobayashi
-
Patent number: 5082651Abstract: Pharmaceutical compositions suitable for intra-rectal administration in the form of a foam are described which comprise a therapeutically effective amount of 5-aminosalicylic acid, a pharmaceutically acceptable aqueous carrier therefor, and means for generating a foam.Type: GrantFiled: April 25, 1990Date of Patent: January 21, 1992Assignee: Smith Kline & French Laboratories LimitedInventors: John N. C. Healey, Marshall Whiteman
-
Patent number: 5041431Abstract: A pharmaceutical composition containing as active ingredient 5-aminosalicyclic acid or a pharmaceutically acceptable salt or ester thereof allow the treatment of colitis ulcerosa or Crohn's disease by oral administration. A particular slow-release tablet formation and its preparation is disclosed.Type: GrantFiled: June 26, 1989Date of Patent: August 20, 1991Assignee: Farmaceutisk Laboratorium Ferring A/SInventor: Soren Halskov
-
Patent number: 5013727Abstract: A pharmaceutical composition containing as active ingredient 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof allow the treatment of colitis ulcerosa or Crohn's disease by oral administration. A particular slow-release tablet formation and its preparation is disclosed.Type: GrantFiled: June 26, 1989Date of Patent: May 7, 1991Assignee: Farmaceutisk Laboratorium Ferring A/SInventor: Soren Halskov
-
Patent number: 5010069Abstract: An aqueous solution of 5-aminosalicylic acid (5-ASA) and a nontoxic alkali, alkali metal or alkaline earth metal salt of 5-aminosalicylic acid having a pH of 3-5 is disclosed. The sole buffer in the solution is that intrinsically formed by 5-aminosalicylic acid and its alkali, alkali metal or alkaline earth metal salt. The solutions preferably also contain an antioxidant and a metal complexing agent. In preferrred practice, the 5-ASA salt is formed in situ by addition of an alkali, alkali metal or alkaline earth metal hydroxide to a solution of 5-ASA. The solution is stable and does not significantly discolor due to 5-ASA decomposition for extended periods of time.Type: GrantFiled: May 15, 1989Date of Patent: April 23, 1991Assignee: Marion Laboratories, Inc.Inventors: Carey B. Bottom, Margaret N. Kwoka
-
Patent number: 4975426Abstract: Pharmaceutical compositions and methods of using same comprising aspirin, sodium salicylate, salicylamide or acetaminophen, in combination with a non-sedating antihistamine and optionally one or more other active components selected from a decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold, cold-like and/or flu symptoms and the discomfort, pain, headache, fever and general malaise associated therewith.Type: GrantFiled: February 24, 1989Date of Patent: December 4, 1990Assignee: Analgesic AssociatesInventors: Abraham Sunshine, Eugene M. Laska, Carole E. Siegel
-
Patent number: 4960765Abstract: A pharmaceutical composition containing as active ingredient 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof allow the treatment of colitis ulcerosa or Crohn's disease by oral administration. A particular slow-release tablet formation and its preparation is disclosed.Type: GrantFiled: June 26, 1989Date of Patent: October 2, 1990Assignee: Farmaceutisk Laboratorium Ferring A/SInventor: Soren Halskov
-
Patent number: 4942031Abstract: A composition comprising LYCD together with known topically active useful medicinal agents such as antiwrinkling, antibiotic, anticancer, antifungal, antiinflammatory, antiviral, steroid, and wound healing agents. The LYCD works together with the other active ingredients to achieve a synergistic result more effective than can be obtained from the topical agents individually, and more effective than could be predicted from the mere addition of the known efficacies of the individual ingredients.Type: GrantFiled: August 16, 1989Date of Patent: July 17, 1990Inventor: Robert H. Levin
-
Patent number: 4940580Abstract: A sustained release dosage form of labetalol hydrochloride is disclosed comprising the active ingredient in a polymeric matrix of hydroxypropylmethylcellulose and polyvinylpyrrolidone and a pharmaceutically acceptable organic acid.Type: GrantFiled: February 2, 1989Date of Patent: July 10, 1990Assignee: Schering CorporationInventors: Surendra Sangekar, Winston A. Vadino
-
Patent number: 4939132Abstract: This invention relates to new 5-alkylsulfonylsalicylanilides and methods for their use. More particularly, the invention relates to compounds of the formula: ##STR1## Wherein Z is a substituted or unsubstituted phenyl ring of from 6 to 30 carbon atoms including substituents, R is a substituted or unsubstituted alkylsulfonyl group of from 1 to 20 carbon atoms including substitutents; and X is a radical selected from the group consisting of --CN, --NO.sub.2, --H, halogen, lower alkyl or lower haloalkyl.The above compounds and compositions containing them are effective antiseptics against a wide range of microorganisms, especially bacteria, and are surprisingly highly effective against microorganisms, particularly S. mutans, prevalent in dental plaque.Type: GrantFiled: April 15, 1985Date of Patent: July 3, 1990Assignee: The Research Foundation of State University of New YorkInventors: Robert A. Coburn, Richard T. Evans, Robert J. Genco, Michael T. Clark
-
Patent number: 4939145Abstract: Phenothiazone derivatives and analogs thereof, pharmaceutical compositions and methods of treatment are disclosed. These compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation.Type: GrantFiled: January 19, 1989Date of Patent: July 3, 1990Assignee: Merck Frosst Canada, Inc.Inventors: Cheuk K. Lau, Joshua Rokach, Christiane Yoakim, Rejean Fortin, Yvan Guindon
-
Patent number: 4939133Abstract: The present invention relates to novel N-substituted 2-hydroxybenzamide and N-substituted 2-hydroxy-.alpha.-oxo-benezene acetamide compounds pharmaceutical compositions, and methods of use for therefore for the treatment of diseases in which products having lipoxygenase enzyme activity contribute to the pathological condition. Selected novel intermediates are also the present invention.Type: GrantFiled: October 1, 1985Date of Patent: July 3, 1990Assignee: Warner-Lambert CompanyInventors: David T. Connor, Daniel L. Flynn, Wiaczeslaw A. Cetenko, Jagadish C. Sircar, Charles F. Schwender, Elizabeth A. Johnson, Roderick J. Sorenson, Paul C. Unangst
-
Patent number: 4880794Abstract: A pharmaceutical composition containing as active ingredient 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof allow the treatment of colitis ulcerosa or Crohn's disease by oral administration. A particular slow-release tablet formation and its preparation is disclosed.Type: GrantFiled: June 8, 1987Date of Patent: November 14, 1989Inventor: Soren Halskov
-
Patent number: 4873232Abstract: Novel alkoxycarbonylamino benzoates and related copounds (carbamoyl benzoates) are disclosed for treatment of auto-immune disease states, such as arthritis.Type: GrantFiled: October 29, 1986Date of Patent: October 10, 1989Assignee: SyntexInventors: Alexander Krantz, John M. Young
-
Patent number: 4863967Abstract: A compound having the structural formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are hydrogen, C.sub.1 -C.sub.6 alkyl, halogen or C.sub.1 -C.sub.4 alkoxy is disclosed. These compounds demonstrate utility as hypolipidemic agents.The present invention is also directed to a process for controlling lipidemia in mammals comprising treating mammals with a lipidemia controlling effective amount of the above-defined compound.Yet another aspect of the present invention is embodied in a pharmaceutical composition comprising the above compound and a pharmaceutically acceptable carrier therefor.Type: GrantFiled: June 16, 1986Date of Patent: September 5, 1989Assignee: Research CorporationInventors: Iris H. Hall, Steven D. Wyrick
-
Patent number: 4816244Abstract: Medium molecular weight alcohols (for example aliphatic alcohols, such as trihydroxypentane and trihydroxyhexane, and aromatic alcohols, such as benzylalcohol) have been found to provide unexpected stability to dye and stain solutions. In addition, the use of these alcohols does not involve the negatives found in other dye stabilizers, for example extreme flammability and toxicity. The novel alcohols have been found to provide benefit to many dye systems.Type: GrantFiled: February 14, 1986Date of Patent: March 28, 1989Assignee: Sigma Chemical CompanyInventor: William H. Starkweather
-
Patent number: 4788183Abstract: A method for treating dyslipidemia in a human is disclosed, the dyslipidemia is characterized by an HDL serum cholesterol level of below about 50 milligrams per deciliter. The method consists of the administration to said human of a therapeutically effective amount of 5-{(R)-1-hydroxy-2-[(R)-(1-methyl-3-phenylpropy)amino]-ethyl}salicylamide, 5-{(S)-1-hydroxy-2-[(R)-(1-methyl-3- phenylpropyl)amino]ethyl}salicylamide or a pharmaceutically acceptable salt thereof or a mixture thereof.Type: GrantFiled: November 30, 1987Date of Patent: November 29, 1988Assignee: Schering CorporationInventor: William Darrow
-
Patent number: 4781913Abstract: Disclosed is a pharmaceutical composition for use in desensitizing hypersensitive dentin or eliminating odontalgia comprising N-methacryloyl aminosalicylic acid as an active ingredient. The composition may further include an unsaturated compound and a polymerization initiator optionally for retaining the densensitizing effect.Type: GrantFiled: April 2, 1987Date of Patent: November 1, 1988Assignee: Eiichi MasuharaInventors: Eiichi Masuhara, Hiroyasu Hosoda
-
Patent number: 4742069Abstract: Dihydropyridine derivatives of the formula ##STR1## wherein the symbols A, R and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as described herein.Compounds of formula I have a pronounced calcium-antagonistic activity and can accordingly be used as medicaments, especially for the control or prevention of angina pectoris, ischemia, high blood pressure and/or migraine.Type: GrantFiled: June 17, 1985Date of Patent: May 3, 1988Assignee: Hoffmann-La Roche Inc.Inventors: Roland Jaunin, Henri Ramuz
-
Patent number: 4725590Abstract: A topically and systemically administered anti-inflammatory composition for human and for veterinary consumption which comprises compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are defined hydrocarbon attachments and Y is --OH or a phenolic ester group derived from the reaction of such --OH group with a carboxylic acid halide or anhyride.In typical compounds covered by said general formula(a) R.sub.1 is H, R.sub.2 is 5,n-octanoyl, Y is hydroxy and R.sub.3 is p-trifluoromethylphenyl;(b) R.sub.1 is H, R.sub.2 is 5,n-decanoyl, Y is hydroxy and R.sub.3 is benzothiazol-2-yl and(c) R.sub.1 is H, R.sub.2 is 5,n-decanoyl, Y is acryloyloxy and R.sub.3 is p-nitrophenyl.Type: GrantFiled: September 10, 1985Date of Patent: February 16, 1988Assignee: Lever Brothers CompanyInventor: Thomas W. Ritchey
-
Patent number: 4713377Abstract: Blockage of the bowel is ameliorated by the rectal administration of .beta.-diethylaminoethyl 3-phenyl-2-hydroxybenzoate (biphenamine).Type: GrantFiled: December 1, 1986Date of Patent: December 15, 1987Inventor: Thomas L. Schulte
-
Patent number: 4708953Abstract: Salicylamide derivatives of the formula ##STR1## in which X is a halogen atom, are active against fungi, especially those which result in clubroot of cruciferous plants.Type: GrantFiled: September 10, 1985Date of Patent: November 24, 1987Assignee: Nihon Tokushu Noyaku Seizo K.K.Inventors: Yoshio Kurahashi, Kozo Shiokawa, Toshio Goto, Shinzo Kagabu, Noboru Matsumoto, Koichi Moriya
-
Patent number: 4708873Abstract: Debridement of ulcerated necrotic tissue of the skin or mucous membrane is promoted by applying thereto an aqueous solution of biphenamine and aloe vera, the former preferably being dissolved in the latter, thereby promoting healing of the lesion.Type: GrantFiled: January 29, 1986Date of Patent: November 24, 1987Inventor: Thomas L. Schulte
-
Patent number: RE33239Abstract: A packaged enema solution or suspension consisting essentially of an effective amount of 5-ASA or a pharmaceutically acceptable salt or ester thereof, a chelating agent, in antioxidant and a buffer, the solution or suspension having a pH value of from 4 to 7 and being contained in a plastic bottle under an inert gas, the plastic bottle being packaged in a diffusion-tight light-impervious package in the same inert gas as is present in the bottle.Type: GrantFiled: May 12, 1989Date of Patent: June 26, 1990Assignee: Farmaceutisk Laboratorium Ferring A/SInventor: Soren Halskov